Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain
2.
Have the Harms of Lung Cancer Screening Been Exaggerated?
3.
For incarcerated people, study shows gaps exist in quality of cancer care
4.
After all, Pulled Myeloma Drug May Help Treat the Illness.
5.
Ranking of the Best US Hospitals for Psychiatric Care.
1.
Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength
2.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
3.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
4.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
5.
Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge